about
Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaProbenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cellsTargeting bone metabolism in patients with advanced prostate cancer: current options and controversies.Cancer-targeted therapies and radiopharmaceuticalsDynamic interplay between bone and multiple myeloma: emerging roles of the osteoblastBone metastasis and the metastatic niche.Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.Bone metastasis risk factors in breast cancer.Adipocyte-derived players in hematologic tumors: useful novel targets?The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cellsHigh CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma.Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?Prospects of adjuvant RANKL inhibition in breast cancer?High Prevalence of Vitamin D Deficiency in Patients with Bone Tumors.[Diagnostics in osteology].[Bone metastases : New aspects of pathogenesis and systemic therapy].[Regulation of bone metabolism in osteoporosis : novel drugs for osteoporosis in development].Role of WNT5A receptors FZD5 and RYK in prostate cancer cells.Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis
P2860
Q28081996-CDA71564-0C65-4204-A1D8-7B50C570403EQ34967135-45B235D4-5446-47B6-8176-88C8EF9D8EFCQ35087364-BA47C1F9-3F55-4704-9B11-3A3E0C8C4F22Q35683440-DAB8A5B3-4792-4DB0-863D-6B1E57FC4F29Q36086488-A206F11A-A5B9-4195-8354-DB344C1CB06EQ36259458-1FC0EB90-3299-41E9-A485-D62A2903EADCQ36667402-79420BD5-7935-4771-A457-FF71FE0F8CAEQ37629662-DB330867-9F31-4FBA-BD8A-67860A85CF1CQ38259527-FECE237F-3700-42CC-8435-4D4106E2CAFFQ38817011-0C0048B1-2306-41E5-B845-A328396A5D7BQ38823772-0770BC30-EB21-45E0-B87C-401C2956F8C4Q38981228-6562E433-6B05-48F4-BD34-05959752BC56Q40930271-0A4D435B-E08E-47B2-B623-12CA1321CEDCQ41273764-20F821DC-C4E0-4DA2-B6B5-203A80108089Q43142242-1B7D201B-75A9-4C8B-95E6-6C1143D133F8Q47299545-EB2A1324-6EC6-49A0-A55A-1AC4165744C0Q52982319-648A0582-7A60-4C7E-BAFF-0D289F6B67AAQ53062244-328ABA40-EEAA-488B-AD4E-FF9082DA04D6Q53813299-19690A0C-A561-429B-A2DE-B96C246857A9Q55332428-AED6CD0E-98CC-4AD1-B1D6-AFB5EF95D410Q57071021-68DC8808-B18F-4558-83FE-99BFF096B417
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Endocrine aspects of bone metastases.
@en
type
label
Endocrine aspects of bone metastases.
@en
prefLabel
Endocrine aspects of bone metastases.
@en
P2093
P1476
Endocrine aspects of bone metastases.
@en
P2093
Franz Jakob
Robert E Coleman
Tilman D Rachner
P304
P356
10.1016/S2213-8587(13)70203-1
P577
2014-01-24T00:00:00Z